Floatz logo

Adebrelimab

Head and Neck Squamous Cell Carcinoma

Hansoh BioMedical R&D CompanyPhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
65/ 100

Competitive context

129 Active assets in the Head and Neck Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Epirubicin
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Docetaxel
National Cancer Institute (NCI)
Phase 3B
(+)-VINCRISTINE
Neonc Technologies, Inc.
Phase 2B
Durvalumab
University Health Network, Toronto
Phase 2B

View all 50 →

Same molecule, other indications

Adebrelimab is also rated in:

Metastatic Colon CancerDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
67 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →